Wu, W., Chen, J., Deng, H., Jin, L., He, Z., Rao, N., . . . Liu, J. (2021). Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: A randomized pilot trial. BMC Cancer.
Trích dẫn kiểu ChicagoWu, Wei, et al. "Neoadjuvant Everolimus Plus Letrozole Versus Fluorouracil, Epirubicin and Cyclophosphamide for ER-positive, HER2-negative Breast Cancer: A Randomized Pilot Trial." BMC Cancer 2021.
Trích dẫn MLAWu, Wei, et al. "Neoadjuvant Everolimus Plus Letrozole Versus Fluorouracil, Epirubicin and Cyclophosphamide for ER-positive, HER2-negative Breast Cancer: A Randomized Pilot Trial." BMC Cancer 2021.
Cảnh báo: Các trích dẫn này có thể không phải lúc nào cũng chính xác 100%.